You just read:

RXi Pharmaceuticals and Thera Neuropharma Enter into an Exclusive License Agreement for RXi's Self-Delivering RNAi (sd-rxRNA®) Platform Targeting SOD1 to Develop Therapeutics for Neurodegenerative Diseases, such as ALS (Lou Gehrig's Disease)

News provided by

RXi Pharmaceuticals Corporation

03 May, 2016, 07:12 ET